ClinicalTrials.gg
CompletedNCT00337493Updated Sep 17, 2012

Pharmacogenetic Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.

A Phase 4 interventional study of mycophenolate mofetil [CellCept] and mycophenolate mofetil [CellCept] in Kidney Transplantation, sponsored by Hoffmann-La Roche. Completed at 20 sites in United States. Open to participants aged 13 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-09-17.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
155
Allocation
Randomized
Ages
13 Years to 75 Years
Sex
All
01

Study summary

This study will determine which, if any, allelic variants of mycophenolic acid (MPA) metabolizing enzymes, drug transporters and drug targets are associated with the observed variation in pharmacokinetic and pharmacodynamic outcomes observed with CellCept usage. Patients participating in study ML17225 will be eligible for this pharmacogenetic investigation, and will have one additional blood sample taken during the study. The anticipated time on study treatment in study ML17225 is 1-2 years, and the target sample size is 500+ individuals.

02

Conditions studied

  • Kidney Transplantation
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients participating in study ML17225.

Exclusion criteria

Exclusion Criteria:

  • N/A.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
155 participants (actual)

Study arms

  • Experimental
    1

    Drug: mycophenolate mofetil [CellCept] · Drug: Cyclosporine or tacrolimus

  • Experimental
    2

    Drug: mycophenolate mofetil [CellCept] · Drug: Cyclosporine or tacrolimus

  • Experimental
    3

    Drug: mycophenolate mofetil [CellCept] · Drug: Cyclosporine or tacrolimus

Interventions

06

What researchers measure

Primary outcomes

  1. Correlation of allelic variants of MPA metabolizing genes, membrane transporter genes and target genes with AUC, transplant rejection, GER and drug side effects.

    Time frame: Throughout study

Secondary outcomes

  1. Viral kinetics

    Time frame: Throughout study

07

Study locations

20 sites
  • Birmingham, Alabama 35294, United States
  • Little Rock, Arkansas 72205-7199, United States
  • Los Angeles, California 90057, United States
  • Denver, Colorado 80262, United States
  • Gainesville, Florida 32610-0224, United States
  • Orlando, Florida 32804, United States
  • Augusta, Georgia 30912, United States
  • Chicago, Illinois 60637, United States
  • Indianapolis, Indiana 46202-5167, United States
  • Lexington, Kentucky 40536-0293, United States
  • Shreveport, Louisiana 71130, United States
  • Boston, Massachusetts 02111, United States
  • Hackensack, New Jersey 07601, United States
  • Livingston, New Jersey 07039, United States
  • Buffalo, New York 14203, United States
  • Chapel Hill, North Carolina 27599, United States
  • Fargo, North Dakota 58122, United States
  • Portland, Oregon 97210, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Madison, Wisconsin 53792, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2006
First posted
Jun 16, 2006
Start
Dec 2005
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Last update
Sep 17, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00337493
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 16, 2006
Start date
Dec 2005
Primary completion
Jan 2008
Completion
Jan 2008
Last update
Sep 17, 2012

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mycophenolic Acid · Cyclosporine · Tacrolimus

Start the discussion